Overview

14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy

Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
1. Test for Helicobacter pylori. The test items include urease test, histology, bacterial culture, serology, and urea breath test. At least two positive results can be used to confirm the diagnosis. 2. To ensure that the research results are not artificially distorted, this trial is a randomized study. Random allocation (which means that the subjects will use the "random number table generated by a computer similar to the lottery" to determine the treatment group) accept one of the following schemes (1:1:1).
Phase:
Phase 4
Details
Lead Sponsor:
Kaohsiung Medical University
Treatments:
Amoxicillin
Clarithromycin
Metronidazole
Rabeprazole